Trial reportAmerican journal of hematology2015
Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis.
Trial report in American journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01757418 (Phase 1-2 Trial of Gamunex), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Intravenous immunoglobulins in the management of acute chest syndrome in two Jehovah's Witnesses with sickle cell disease.Haematologica · 2026Article
- Review
- Sickle cell disease: progress towards combination drug therapy.British journal of haematology · 2021Review
- Sickle cell vaso-occlusion: The dialectic between red cells and white cells.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Innate immune cells, major protagonists of sickle cell disease pathophysiology.Haematologica · 2020Review
- Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.Therapeutic advances in hematology · 2020Review
- Drug Therapies for the Management of Sickle Cell Disease.F1000Research · 2020Review
- Emerging disease-modifying therapies for sickle cell disease.Haematologica · 2019Review
- Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics.The American journal of pathology · 2019Review
- Therapeutic strategies for sickle cell disease: towards a multi-agent approach.Nature reviews. Drug discovery · 2019Review
- New insights into the pathophysiology and development of novel therapies for sickle cell disease.Hematology. American Society of Hematology. Education Program · 2018Review
- Safety and efficacy of plerixafor dose escalation for the mobilization of CD34Haematologica · 2018Article
- Advances in new drug therapies for the management of sickle cell disease.Expert opinion on orphan drugs · 2018Article
- Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease.Blood advances · 2017Article
- Developing new pharmacotherapeutic approaches to treating sickle-cell disease.ISBT science series · 2017Article
- Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli.JCI insight · 2017Article
- Emerging point-of-care technologies for sickle cell disease screening and monitoring.Expert review of medical devices · 2016Review
- Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.American journal of hematology · 2016Review
- Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Translational research : the journal of laboratory and clinical medicine · 2016Article
- New insights into sickle cell disease: mechanisms and investigational therapies.Current opinion in hematology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Intravenous immunoglobulin (IVIG) decreases neutrophil adhesion to endothelium and red blood cell-neutrophil interactions in sickle cell mice undergoing vaso-occlusion. In this Phase I clinical trial of sickle cell anemia (SCA) patients admitted with pain crisis, we evaluated the status of adhesion molecules on neutrophils in control and IVIG-treated subjects pre- and post-infusion up to 800 mg/kg, the same dose used in murine studies. Mac-1 function significantly decreased from baseline in the low-dose IVIG (200-400 mg/kg) cohorts. IVIG-related adverse events may have occurred in the high-dose (600-800 mg/kg) cohorts. There were no significant increases in neutrophil and leukocyte counts, suggesting that IVIG may more selectively inhibit Mac-1 function as opposed to neutrophil adhesion. This study provides the first in-human validation of pre-clinical murine studies that IVIG can decrease Mac-1 function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.